Gaucher disease, the most prevalent glycolipid storage disorder, is classically subdivided into types according to the presence or absence of neurological involvement. Type I has hitherto been considered non-neuronopathic. We present six cases and a review of the literature of Parkinsonian symptoms in type I Gaucher disease patients. The hallmark of this atypical Parkinsonian syndrome is a relatively severe clinical course with early appearance of neurological signs in the 4th to 6th decade of life, aggressive progression of the signs and refractoriness to conventional anti-Parkinson therapy. We discuss the implications of these findings in the light of enzyme replacement therapy for Gaucher disease.
Introduction
Gaucher disease, the most prevalent sphingolipid storage disorder, is a defect of glucocerebrosidase activity due to mutations in the gene encoding the lysosomal enzyme glucocerebrosidase, with consequent accumulation of the glycolipid glucocerebroside in the cells of the monocyte-macrophage system. 1 The disease has three clinical forms, distinguished by the presence and aggressivity of neurological complications. 2 Type I, the non-neuronopathic form, is the most common, with an ethnic predilection among Ashkenazi Jews. 3 ' 4 Presentation in type I is variable, with onset of symptoms noted in infants as well as in the elderly; the course of the disease is also variable with sudden accelerations at all ages. Even among family members with the same genotype, the severity of the disease may differ. Clinical heterogeneity is most characteristic of type I, and many patients with this type remain virtually asymptomatic and are only diagnosed during evaluation for an unrelated disorder or because of family screening of a symptomatic relative. 5 The presence of the single most common mutation, N370S (1226G) on one allele appears to be protective of development of a neuronopathic form, and indeed the genotype N370S/N370S is the most common among type I patients. 3 ' 6 Type II Gaucher disease (infantile, acute neuronopathic) and type III (juvenile, subacute neuronopathic) are rare and panethnic. In type II, the neurological signs become evident during the first months of life, including oculomotor apraxia, strabismus, hypertonia and retroflexion of the head. These contribute to death (of aspiration pneumonia in most cases) before the age of 2 years. 7 Type III disease is characterized by similar but less fulminant symptoms, including horizontal supranuclear gaze palsy, myoclonic epilepsy, dementia, ataxia or spasticity, and is usually fatal before early adulthood. 8 ' 9
Methods

Patients
Six patients, all of whom had been diagnosed with Gaucher disease on the basis of bone-marrow aspir-ate or splenic biopsy specimen, and on the basis of decreased glucocerebrosidase activity, developed a Parkinsonian syndrome: one non-Jewish patient from Italy, and five Ashkenazi Jewish patients from Israel. There were three males and three females; mean age at diagnosis was 32 (range 15-45) years. Most suffered from anaemia and/or thrombocytopenia, and moderate hepatosplenomegaly, and three had undergone splenectomy. Four of six patients complained of bone pains or other skeletal involvement.
Mean age at onset of Parkinsonian symptoms was 48.8 (range 41-55) years. The common extrapyramidal signs were intention tremors (in three patients), rigidity and bradykinesis (in all patients), expressionless facies (in two patients) and slurred or monotonous speech (in four patients). One patient had myoclonic jerks. Two patients had received psychiatric treatment for depressive or psychotic episodes. The course of the neurological manifestations was well-recorded in four patients, one patient refused all medical care and was lost to follow-up, and another patient died during initial evaluation. Of the four patients with documented clinical histories, four had neurological symptoms and signs that were refractory to Levodopa or other anti-Parkinsonian medications. Two patients underwent stereotactic thalamotomy for relief of their neurological symptoms, with only partial responses.
Statistical analyses
The age of onset of Parkinsonian symptoms in the Gaucher patients in this study who were of Ashkenazi Jewish extraction was 47.5+4.76 years. We have compared this group to 41 randomly assigned Ashkenazi Jewish patients with the clinical diagnosis of Parkinson disease, who underwent an enzymic assay, and in whom Gaucher disease was excluded. The age of onset of symptoms in the group of patients with Parkinson disease was 61.4 + 10.24 years. The Student's t-test for two groups revealed this to be significant: p = 0.002; as did the non-parametric U-test (Mann-Whitney): p = 0.005. The age of onset of Parkinsonian symptoms in Ashkenazi Jewish Gaucher patients is thus significantly earlier than in patients with Parkinson's disease in the same population without Gaucher disease.
Discussion
Anecdotal reports of adult patients with type I Gaucher disease but with neurological symptoms, such as seizures, psychosis or mental illness and deterioration have previously been considered lateonset type III disease or unrelated concurrence of symptoms. 10 14 reported a mother and two adult children, the latter of whom were diagnosed by bone-marrow aspirate as having Gaucher disease at ages 21 and 20 years, respectively. All three demonstrated neuropsychiatric abnormalities including psychosis, depression, mental deterioration and confusion; the mother and daughter were both diagnosed as having Parkinson syndrome. In a series of four patients, Sack 15 emphasized the variegated clinical picture of type I Gaucher disease, including one patient with 'atypical Parkinson syndrome'. McKeran ef a/. 16 discussed the case of tapetoretinal degeneration in a woman with moderate Gaucher disease for 38 years, whose extrapyramidal symptoms were initially controlled by dopamine but who was unresponsive to all medications within two years. Turpin ef a/. 17 reported a Gaucher patient with Parkinson-like symptoms which they considered to be causally related. The nature of the putative association between Gaucher disease and extrapyramidal symptoms remains to be elucidated. It appears, however, that there is no overt relationship between the presence of CNS symptoms and pathological findings in the brain. In most instances where Gaucher's cells have been identified in the brains of patients with type I disease, the cells were observed in the perivascular space 18 and in sheets in the meninges. 19 However, those pathological findings occurred in patients without neurological symptoms. Conversely, in one of our patients, post-mortem examination of the brain and meninges was unremarkable, and no cellular infiltration with Gaucher cells was observed. The absence of Gaucher's cells in the nervous system was also noted in some cases of neuronopathic Gaucher disease, 20 thus it is clearly not a requirement for the diagnosis of neurological complications of Gaucher disease. 
